Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials
Authors:
- Neil J. ShahNSNeil J. Shah
- Alexandra Della PiaAPAlexandra Della Pia
- Tianmin WuTWTianmin Wu
- Aquino WilliamsAWAquino Williams
- Melinda WeberMWMelinda Weber
- Brittany SinclaireBSBrittany Sinclaire
- Elli Gourna PaleoudisEPElli Gourna Paleoudis
- Adil AlaouiAAAdil Alaoui
- Shaked Lev-AriSLShaked Lev-Ari
- Shari AdamsSAShari Adams
- Jordan KaufmanJKJordan Kaufman
- Sahil B. ParikhSPSahil B. Parikh
Open Access
Abstract
Regulatory approval of immune checkpoint inhibitors (ICIs) was based on results of large, randomized clinical trials, resulting in limited outcomes data in patient cohorts typically underrepresented in such trials. The objective of this study was to evaluate the efficacy and safety of ICIs in these unique patient cohorts. This is a multicenter, retrospective analysis of real-world data at six academic and community clinics in the United States from 1 January 2011 to 1 April 2018. Patients were included if they had received at least one cycle of ICI treatment. Unique patient cohorts included age > 75 years, non-White race, positive smoking history, ECOG performance status (PS) ≥ 2, BMI ≥ 30 kg/m2, autoimmune diseases (AIDs), chronic viral infections (CVI), extensive prior lines of therapy (LOTs), or >three metastatic sites. Immune-related adverse events (irAEs), overall survival (OS), and time to treatment failure were evaluated in the entire cohort and in NSCLC patients treated with PD-(L)1 monotherapy. Outcomes and their association with unique patient cohorts were compared on univariate analysis and multivariate analysis to those without a particular characteristic in the entire NSCLC PD-(L)1 monotherapy cohorts. In total, 1453 patients were included: 56.5%—smokers, 30.4%—non-White, 22.8%—elderly, 20.8%—ECOG PS ≥ 2, 15.7%—history of AIDs, and 4.7%—history of CVI. The common ICIs were nivolumab (37.1%) and pembrolizumab (22.2%). Black patients, compared to White patients, experienced fewer irAEs (OR 0.54, p < 0.001). An ECOG PS of ≥2 (HR = 2.01, p < 0.001) and an increased number of previous LOTs were associated with poor OS (the median OS of 26.2 vs. 16.2 vs. 9.6 months for one vs. two vs. three prior LOTs, p < 0.001). The above results were confirmed in anti-PD-(L)1 monotherapy non-small cell lung cancer patients (n = 384). Overall, ICIs were safe and efficacious in these typically underrepresented patient cohorts. We noted ECOG PS ≥ 2 and an increased prior LOTs were associated with poor ICI efficacy, and Black patients, compared to White patients, experienced fewer irAEs.Keywords
Funding Information
- NCI Cancer Center Support Grant (P30 CA008748, P30 CA051008)
- Georgetown-Lombardi Comprehensive Cancer Center (P30 CA008748, P30 CA051008)
- Gieseman Melanoma Research Fund and Stan and the Linda Sher Immunotherapy Research Fund (P30 CA008748, P30 CA051008)
This publication has 38 references indexed in Scilit:
- Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor ImmunotherapyJAMA Oncology, 2022
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerJAMA Oncology, 2021
- Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancerCancer, 2020
- The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidenceCancer Treatment Reviews, 2020
- Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung CancerJAMA Oncology, 2020
- CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEuropean Journal of Cancer, 2020
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyArthritis & Rheumatology, 2019
- Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage CancerJAMA Oncology, 2019
- Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programmeEuropean Journal of Cancer, 2018
- Prevalence of Autoimmune Disease Among Patients With Lung CancerJAMA Oncology, 2016